SUNNYVALE, Calif., Nov. 18, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the first CyberKnife® System in Manhattan is now treating patients at Winthrop University Hospital's NYCyberKnife Center. Winthrop's decision to install the latest generation CyberKnife M6™ System reinforces its growing reputation as a dedicated radiosurgery device that delivers extremely precise full-body treatments while maximizing patients' quality of life during and after treatment.
The CyberKnife M6 System's true robotic mobility enables it to deliver radiation beams from a wide range of angles around the body, precisely targeting tumors while avoiding healthy tissue. It can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney. The treatment – which delivers high doses of radiation to tumors with extreme accuracy – may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, non-surgical option.
The CyberKnife System's ability to automatically stay on target despite patient and tumor motion is what truly differentiates it from other forms of radiation therapy systems. It automatically follows the tumor throughout the treatment process, intelligently delivering radiation with sub-millimeter precision. This unique, dynamic motion compensation feature enables clinicians to precisely maximize dose, minimize side effects and maximize patient comfort.
Joshua H. Levine, president and chief executive officer of Accuray: "The CyberKnife System is a transformative innovation, changing the face of cancer treatment and enabling clinicians to help their patients live longer, better lives. We're honored that Winthrop selected our system and want to congratulate the team as they expand their significant clinical expertise to treating patients in Manhattan with the CyberKnife System."
Jonathan Haas, MD, chief, Division of Radiation Oncology at Winthrop-University Hospital: "The Winthrop team is excited to be the first center in Manhattan to offer patients requiring radiation therapy the option to receive treatment with the CyberKnife System. We saw the considerable benefits the system has provided to our patients in Mineola, so when considering alternatives for our new location, it was an easy choice. We selected the CyberKnife M6 System because it includes the features and precision of the previous model, with the potential to provide faster treatment times and expand access to more patients."
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops,
manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to adoption and acceptance of the company's products, clinical experience, clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's report on Form 10-Q, filed on November 7, 2014, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated